Companies Dominating the Irritable Bowel Syndrome Drugs Landscape
- Abbott Services
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Ardelyx, Inc.
- Astellas Pharma Inc.
- AstraZeneca
- GlaxoSmithKline Plc
- Johnson & Johnson Services, Inc.
- Novartis AG
- Ironwood Pharmaceuticals, Inc.
- Synergy Pharma Consultancy Private Limited
- Synthetic Biologics, Inc
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Irritable Bowel Syndrome Drugs Market in 2025 is estimated at USD 4.43 billion.
The global market size was around USD 4.14 billion in 2024 and is likely to expand at a CAGR of more than 8.7%, surpassing USD 12.25 billion revenue by 2037.
North America takes the lead, driven by fecal incontinence treatment needs and efficient care options.
The major players in the market include Abbott Services, Ardelyx, Inc., Astellas Pharma Inc., AstraZeneca, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Ironwood Pharmaceuticals, Inc., Synergy Pharma Consultancy Private Limited, Synthetic Biologics, Inc.
